Catalent Selected to Provide Oral Delivery Systems for GB Sciences’ Proprietary Parkinson’s Disease Therapies
SWINDON, U.K.
, and
LAS VEGAS
, September 26, 2018-- GB Sciences, Inc. (OTCQB: GBLX) and Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that GB Sciences has selected Catalent to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients (“APIs”) for its Parkinson’s disease therapies. A proof of concept study will be conducted by Catalent at its Swindon, U.K. facility to evaluate GB Sciences’ clinical candidates GBS101, GBS102, and GBS103 using Catalent’s proprietary Zydis® Orally Disintegrating Tablet (ODT) technology. GB Sciences’ three patent-pending APIs for Parkinson’s disease are complex mixtures containing up to nine individual components that function synergistically. Preclinical studies have shown that these cannabinoid-containing complex mixtures are more potent than would have been predicted by combining the activity of each individual compound. “To prepare our Parkinson’s disease formulations for human clinical trials, we wanted the ease-of-use offered by Zydis ODTs for our Parkinson’s patients, many of whom may have difficulties in swallowing. Catalent’s proprietary delivery method also potentially offers consistent dosing for our complex cannabinoid- and terpenoid-containing APIs,” explained Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. “The creation of GB Sciences’ proprietary APIs in Zydis ODT formulations is a very important step towards readying them for our Exploratory IND filing and planned phase zero human trial for patients with mild to moderate Parkinson’s disease.” Jonathan Arnold, President of Oral Drug Delivery at Catalent, added, “Dissolving rapidly in the mouth, ODTs are convenient and ease administration, offering an alternate dosage form for patients who have difficulty swallowing, as is sometimes the case with Parkinson’s disease, as well as with geriatric or pediatric patients.” GB Sciences selected Catalent as its development partner due to its expertise in tackling formulation challenges, and ability to achieve the stability and dosing necessary for these novel complex mixtures. In addition to its Zydis technology, Catalent has early development and oral drug delivery solutions available for the efficient delivery of GB Sciences’ proprietary APIs.
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit
www.catalent.com
.
More products. Better treatments. Reliably supplied.™
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to:
http://gbsciences.com
.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
